MindMed To Begin Trading On The Nasdaq April 27

MindMed (NEO: MMED) is moving up to the big leagues. The psychedelics company this morning announced that it has been approved for listing on the Nasdaq Capital Market.

Trading of the company on the big board is expected to begin on April 27, with the company to be listed under the symbol “MNMD”. The company is expected to continue to be listed on the Neo Exchange in Canada as well, with its symbol remaining unchanged.

Commenting on the achievement, CEO JR Rahn stated, “We believe this listing will increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value.”

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

MindMed last traded at $2.67 on the Neo.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Red Cloud Fall Mining Showcase 2026 | Day 2

More Gold Without a Bigger Upfront Bill? | Keith Boyle – New Found Gold

The Red Cloud Fall Mining Showcase 2026 | Day 1

Recommended

First Majestic Lifts Q3 Revenue 38% to US$394.1 Million on Higher Silver Prices

Meghan Markle’s Half-Brother Submitted Evidence Against Their Father, But Now Faces Philippine Police Scrutiny

Related News

Canaccord Reiterates $1.75 Price Target For Mind Medicine Following Roadshow Event

This morning, Canaccord released a flash update for Mind Medicine (NEO: MMED) with highlights from...

Monday, September 28, 2020, 11:02:24 AM

Mind Medicine: Canaccord Genuity Initiates Coverage With C$1.75 Price Target

Yesterday, Canaccord initiated coverage on Mind Medicine (NEO: MMED) with a Speculative Buy rating and...

Wednesday, September 16, 2020, 04:15:00 PM

MindMed Concludes Phase 1 Clinical Trial Of Psychedelic Derivative Drug For Opioid Use Disorder

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, has recently concluded the phase...

Tuesday, January 4, 2022, 10:29:00 AM

Shroom Progress! MindMed Advances Towards a Phase 2 LSD Microdosing Trial For Adult ADHD

Aftermarket MindMed (NEO:MMED) announced they entered into a clinical trial agreement with Maastricht University to...

Monday, May 11, 2020, 10:29:04 PM

Mind Medicine To Raise Up To $100 Million Via ATM Financing

Mind Medicine (NEO: MMED) last night announced that it will be conducting a financing. The...

Tuesday, May 17, 2022, 04:59:05 PM